SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Attention is centered on reports that Papa Johns largest U.S. franchisee has joined Irth Capitals effort to take the company private, reviving buyout hopes. Traders see the franchisees involvement as strengthening the proposal, while others remain skeptical that the board will approve a deal or that negotiations will produce a signed transaction.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks rallied with cybersecurity peers as traders focused on an Evercore ISI survey indicating enterprise security budgets are firming and on escalating vulnerability and AI-driven cyberthreat concerns. The move drew bullish momentum commentary, while some traders questioned whether the sectors gains are justified given lofty valuations.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Phase 3 results for Amgens IMDELLTRA-plus-IMFINZI combination in extensive-stage small-cell lung cancerreported to reduce the risk of death by 58%are driving discussion, with traders viewing the data as a potential growth opportunity. Some also point to Repathas sales growth as a key business driver and debate whether the lung-cancer program can become a major contributor.

TOSHI

TOSHI is drawing attention around a hoped-for breakout after bursts of volume and a modest rebound, with traders repeatedly watching a stubborn resistance zone and speculating about a short squeeze. Bulls are accumulating and anticipating a run, while skeptics point to repeated rejections, weak price action, and broader crypto-market risk; rumors of listings or an announcement remain unconfirmed.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Updated ESMO subgroup analyses from Celcuitys Phase 3 VIKTORIA-1 breast-cancer study are driving discussion, with traders highlighting favorable efficacy for gedatolisib and the potential for a PIK3CA-mutant label expansion. The reaction is split between enthusiasm for the data and concern that CELC still needs to demonstrate commercial uptake and revenue; some posts also debate whether the share price reflects the clinical results.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Promising lung-cancer trial updates for BioNTechs oncology pipeline, including pumitamig and gotistobart, are drawing attention, with traders highlighting encouraging response and survival data. The reaction is bullish but tempered by questions about how durable the results are and lingering concerns over earlier clinical setbacks and leadership changes.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare shares are drawing attention after a sharp gain tied to the PHP2Shell web-software vulnerabilities: traders see its web application firewall as a potential beneficiary as site operators seek protection, alongside a broader cybersecurity-stock rally. Some participants are bullish on the security-demand angle, while others focus on the stocks high valuation and trade the move cautiously.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp, unexplained XCN price spike is drawing attention, with traders noting a large candle and a reported surge before any clear news catalyst. The reaction is divided between dip-buyers expecting a rebound and skeptics calling the repeated spikes and quick reversals pump-and-dump behavior; some also link moves to Bitcoin and broader crypto conditions.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

A broad biotech-sector pullback is the main focus, with IBB hovering near its 50-day moving average after a strong run. Traders describe the dip as a pause while others remain cautious about sector weakness, and several note that large-cap biotech is holding up better than smaller names.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Attention centers on Merck and Modernas Phase 3 melanoma-vaccine results: the personalized vaccine combined with Keytruda met trial endpoints, but traders debate whether the benefit and future commercial potential justify expectations, with some viewing the share pullback as a sell the news reaction. The treatment is not yet approved, and its broader use remains uncertain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Oct. 8, 2026Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would...

Transcript: Ocugen Q2 2026 Earnings Conference Call

Ocugen (NASDAQ:OCGN) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call.
Benzinga APIs provide real-time access to earnings call transcripts and financial data.read more...

Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days

Equity

Ocugen is building an international pathway for OCU400 ahead of key Phase 3 data and a planned U.S. regulatory filing next year.


OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy

Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.

Ocugen (OCGN) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates

Illumina (ILMN) delivered earnings and revenue surprises of +6.50% and +3.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?

Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care

OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.

This account has been verified as an official OCGN representative.

Verified Account

Ocugen

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Ocugen Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Ocugen aims to treat the first retinitis pigmentosa patient in the Bahamas within 90 days, subject to full regulatory approval.</li><li>OCU400 is in a Phase 3 study, with topline data expected in Q1 2027 and a U.S. BLA submission planned for Q2 2027</li><li>Ocugen is pursuing opportunities for commercialization of OCU400 in the Middle East and North Africa.</li></ul>Ocugen (OCGN) was in the spotlight on Friday after the biotech firm announced that its experimental gene therapy for an eye disorder received provisional approval and priority designation in the Bahamas, marking another step in its efforts to expand access to the treatment outside the U.S.The company plans to provide OCU400 through an expanded access program and aims to treat the first patient with retinitis pigmentosa (RP) within 90 days, subject to full approval from the Bahamas’ Longevity and Regenerative Therapies Board. RP is a genetic disease that can progressively damage the retina and can eventually cause blindness.<a href="https://stocktwits.com/symbol/OCGN">OCGN shares</a> were up 3% at the time of writing, trading just above Nasdaq’s required listing compliance of $1.<h2 class="st-heading-2">OCU400’s Global Standing</h2>OCU400 is not yet fully approved for commercial use. Ocugen’s Phase 3<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ocugen.com/news-releases/news-release-details/ocugen-announces-phase-3-limelight-enrollment-completion-ocu400">&nbsp;trial</a> has completed enrollment, with topline results expected in the first quarter of 2027. The company plans a U.S. Biologics License Application (BLA) submission in the second quarter, which could potentially give it a commercial license.In Europe, OCU400 has received orphan medicinal product designation and has been classified as an Advanced Therapy Medicinal Product by European regulators. In the UK, it remains an investigational Phase 3 therapy.Ocugen has also licensed its rights to OCU400 to Kwangdong Pharmaceutical in South Korea and is currently negotiating an exclusive licensing agreement covering the Middle East and North Africa.<h2 class="st-heading-2">Ocugen Has These Two Therapies Up Its Sleeve</h2>Ocugen has two other late-stage eye-disease programs.OCU410ST is in a Phase 2/3 study for Stargardt disease, an inherited condition that causes progressive vision loss. Topline results are expected in Q2 2027. OCU410 is another gene therapy targeting geographic atrophy caused by dry age-related macular degeneration (AMD). The first patient was dosed in its global Phase 3 study earlier this month, with a potential regulatory filing targeted for 2028.To support the development and filing of the therapies, Ocugen expects its cash runway through 2028, after ending the June quarter with $100.1 million in cash and cash equivalents following a convertible-note financing.<h2 class="st-heading-2">Retail’s Take On OCGN</h2>Retail sentiment surrounding OCGN remained ‘neutral’ over the past 24 hours.OCGN shares have declined more than 27% so far in 2026.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/oklo-stock-ubs-cuts-price-target-but-this-government-backed-nuclear-project-could-be-key-catalyst/cZMO4h2RBar">&nbsp;OKLO Stock: UBS Cuts Price Target, But This Government-Backed Nuclear Project Could Be Key Catalyst</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the logo of US biotechnology company Ocugen Inc is displayed on a smartphone

Ocugen is building an international pathway for OCU400 ahead of key Phase 3 data and a planned U.S. regulatory filing next year.

Why Is OCGN Stock Rising Today?

SPDR S&P Biotech ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.7397
Prev Close	$0.79
Open	$0.795
Dividend Yield	0.00%
50-Day Moving Average	$1.10
Beta	1.55
Avg. Volume	8.88M
PE Ratio	-2.91

52-Week High	$2.73
52-Week Low	$0.732
Market Capitalization	$250.84M
EPS (Annual)	-$0.226
Price to Book	-15.15
Revenue Per Employee	$38,043.10

Feed

News

Sentiment

Earnings

Fundamentals

Info

OCGN Fundamentals